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Abstract
Objective
To study intrathecal B-cell activity in leucine-rich, glioma-inactivated 1 (LGI1) antibody en-
cephalitis. In patients with LGI1 antibodies, the lack of CSF lymphocytosis or oligoclonal bands
and serum-predominant LGI1 antibodies suggests a peripherally initiated immune response.
However, it is unknownwhether B cells within the CNS contribute to the ongoing pathogenesis
of LGI1 antibody encephalitis.
Methods
Paired CSF and peripheral blood (PB) mononuclear cells were collected from 6 patients with
LGI1 antibody encephalitis and 2 patients with other neurologic diseases. Deep B-cell immune
repertoire sequencing was performed on immunoglobulin heavy chain transcripts from CSF
B cells and sorted PB B-cell subsets. In addition, LGI1 antibody levels were determined in CSF
and PB.
Results
Serum LGI1 antibody titers were on average 127-fold higher than CSF LGI1 antibody titers.
Yet, deep B-cell repertoire analysis demonstrated a restricted CSF repertoire with frequent
extensive clusters of clonally related B cells connected to mature PB B cells. These clusters
showed intensive mutational activity of CSF B cells, providing strong evidence for an in-
dependent CNS-based antigen-driven response in patients with LGI1 antibody encephalitis but
not in controls.
Conclusions
Our results demonstrate that intrathecal immunoglobulin repertoire expansion is a feature of
LGI1 antibody encephalitis and suggests a need for CNS-penetrant therapies.
*These authors contributed equally to the manuscript.
From the Department of Neurology (K.L.-H., S.W., A.P., S.J., A.L.G., R.D., J.M.G., M.D.G., M.R.W., S.S.Z., H.-C.v.B.), UCSF Weill Institute for Neurosciences; Program in Immunology (K.L.-
H., S.S.Z.), UCSF, San Francisco, CA; Department of Neurology (K.L.-H., G.L.), Klinikum rechts der Isar, Technische Universita¨t Mu¨nchen, Germany; andOxford AutoimmuneNeurology
Group (S.R.I., S.M.), John Radcliffe Hospital, University of Oxford, UK.
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by UCSF.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. 1
Leucine-rich, glioma-inactivated 1 (LGI1) antibody encepha-
litis is characterized by rapidly progressive cognitive impair-
ment, frequent seizures, most characteristically faciobrachial
dystonic seizures, psychiatric disturbances, and sleep
alterations.1,2 These distinctive clinical features, alongside in
vitro and in vivo studies,3,4 and the often rapid response of
seizures to immunotherapies all strongly suggest that LGI1
antibodies are pathogenic.2 However, LGI1 antibody enceph-
alitis can often result in residual cognitive impairment and
neurologic disability: this represents an unmet medical need.2,5
Although CSF LGI1 antibodies are detected in around 90% of
cases, this condition is infrequently associated with CSF
lymphocytosis or oligoclonal bands.2,6,7 Therefore, the CSF
B-cell response has received limited consideration as con-
tributor to pathogenesis or as a potential therapeutic target.
Indeed, very little is known about B cells that participate in the
autoimmune response against LGI1, either in the periphery or
CSF. Here, we applied deep B-cell immune repertoire se-
quencing (DIRS) on sorted peripheral blood (PB) B-cell
subsets and CSF and found strong evidence for intrathecal
antigen-driven immune responses in patients with LGI1 an-
tibody encephalitis. These observations inform disease bi-
ology and suggest CNS B cells as a candidate therapeutic
target in these patients.
Methods
Patient samples
Six patients with LGI1 antibody encephalitis from the Uni-
versity of California, San Francisco (UCSF) Autoimmune
Encephalopathy Clinic underwent collection of paired PB (40
mL) and 10–25 mL of CSF. B-cell subsets were isolated as
described previously.8 As controls, 2 patients with other
noninflammatory neurologic diseases from the same center
were included in the study and their PB and CSF samples
collected accordingly.
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Institutional Review Board of
the UCSF. Written informed consent was obtained from all
participants in the study.
Cell staining and sorting
Ficoll-density separated peripheral blood mononuclear
cells were stained with the following antibodies: CD19
(APC Cy7), immunoglobulin D (IgD) (PE Cy7), CD27
(Qdot605), CD38 (PerCP Cy5.5), and CD3 (Pacific blue)
as previously described.8 B-cell subsets were sorted using
a FACS Aria III (BD Biosciences, Franklin Lakes, NJ) into
naive (CD19+IgD+CD27−), unswitched memory (CD19+
IgD+CD27+), switched memory (CD19+IgD−CD27+
CD38−), double negative (CD19+IgD−CD27−), and
plasmablasts/plasma cells (CD19+IgD−CD27hiCD38hi).
Sorted cells were immediately lyzed in RLT buffer (RNeasy
kit; Qiagen, Hilden, Germany) and stored at −80°C. To
preserve the far lower CSF lymphocyte frequencies,
unfractionated pelleted CSF cells were studied.
ImmunoglobulinmessengerRNAamplification
and immunoglobulin repertoire sequencing
Sequencing work flow was performed as previously described,9
with modifications to sequence human samples. In brief, total
RNA was isolated from CSF cells and PB B-cell subsets, fol-
lowed by reverse transcription into complementary DNA
(cDNA). Next, immunoglobulin G (IgG) heavy chain variable
region (VH) and immunoglobulin M (IgM) VH were ampli-
fied by PCR using the following primers: IgG 39 primer: 59-
GGGAAGACSGATGGGCCCTTGGTGG-39; IgM 39
primer: 59-GCTCGTATCCGACGGG-39; an equimolar mix of
7 VH family 59 primers: VH1: 59-GAARRTYTCCTGCAAG-
GYWTC-39; VH2: 59-CACRCTGACCTGCACCKTCTC-39;
VH3: 59-KARACTCTCCTGTRCAGCCTB-39; VH4: 59-
GTCCCTCACCTGCRCTGTCTM-39; VH5: 59-GAR-
GATCTCCTGTAAGGGTTC-39; VH6: 59-CTCACT-
CACCTGTGCCATCTC-39; VH7: 59-GAAGGT-
TTCCTGCAAGGCTTC-39. PCR conditions were (1)
95°C, 60 seconds; (2) 95°C, 30 seconds; 66.6°C, 30
seconds; 72°C, 60 seconds (33 or 45 cycles); and (3)
72°C, 7 minutes. Specific PCR products were gel purified
and mixed to create 15 pM cDNA libraries, which were
analyzed by Ion Torrent semiconductor sequencing.
Sequence analysis
IGHV and IGHJ gene segment usage, complementarity
determining region (CDR)1-3 amino acid sequence, and
number of somatic hypermutation (SHM) events were
determined as previously described.8,9 Briefly, CDR3
amino acid sequences were determined using a custom-
made pipeline adapted from the AbMining tool,10 and
identified CDR3 regions were related to IGHV and IGHJ
germline genes using IgBlast. To calculate SHM profiles,
sequencing reads with identical CDR1 to CDR3 nucleotide
sequences were grouped as nonredundant (unique) reads,
and SHMs were quantified for this entire region based on
the alignment of reads with germline gene segments.
Glossary
BBB = blood-brain barrier; BCR = B-cell receptor; cDNA = complementary DNA; DIRS = deep B-cell immune repertoire
sequencing; IgD = immunoglobulin D; IgG = immunoglobulin G; IgM = immunoglobulin M; LGI1 = leucine-rich, glioma-
inactivated 1; NMDAR = NMDA receptor; PB = peripheral blood; SHM = somatic hypermutation; SM = switched memory;
UCSF = University of California, San Francisco; VH = heavy chain variable region.
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Compartmental connectivity via bicompartmental clustering
of IgM-VH or IgG-VH from CSF and PB B-cell subsets was
performed as previously described.8 Briefly, clonally related
Ig-VH sequences were identified based on H-CDR3 similarity
(hamming distance of H-CDR3 amino acid sequence less
than 2) and usage of identical Ig germline segments. For
lineage analysis, only Ig-VH sequences with in-frame H-CDR3
and which spanned at least from the 59 end of H-CDR1 to the
39 end of H-CDR3 with a contiguous reading frame were used;
IgTree11 (kindly provided by Dr. Ramit Mehr, Bar-Ilan Uni-
versity, Ramat-Gan, Israel) was used to map the lineage.8 Pu-
tative germline nodes are inferred, and lineage intermediates
not found by DIRS were calculated by IgTree.
Data availability
All next-generation sequencing data and computer code other
than software packages are available from the corresponding
author on reasonable request.
Results
Serum LGI1 antibodies titers were on average 127-fold higher
than CSF LGI1 antibody titers by live cell–based assay using
a membrane-tethered LGI1 construct in all 6 patients with
LGI1 antibody encephalitis (table), none of whom were
asymptomatic at follow-up.12 None of the 6 patients showed
a CSF lymphocytosis or oligoclonal bands on routine CSF
analysis. There was no abnormal enhancement on brainMRI in
any of the patients following the administration of gadolinium,
consistent with no substantial blood-brain barrier (BBB)
opening. DIRS of IgG-VH and IgM-VH was performed from
paired CSF and B-cell subsets sorted from peripheral blood
mononuclear cell samples of the 6 LGI1 antibody encephalitis
patients, and a median of 600,707 sequences per sample (range
165,369–1,586,974) were generated. As expected, circulating
naive B cells had limited somatic mutations and as cells acquired
the postgerminal centermarkerCD27, and class-switched to IgG,
mutations accumulated (figure 1A). These findings are a valida-
tion that DIRS reliably reflects the conventional B-cell matura-
tion stages and suggests that CSF B cells in LGI1 encephalitis
have undergone antigen-driven maturation (figure 1A).
Overall, across all 6 patients, all B-cell subsets of IgG and IgM
isotypes showed high degrees of sequence connectivity in both
PB and CSF compartments (figure 1B). A striking link existed
between PB IgG-expressing SM cells/plasmablasts/plasma
cells and the IgG-expressing CSF B cells, suggesting that class-
switched mature B-cell compartments are consistently con-
nected across the BBB. The CSF B cells often represented
a discrete number of highly expanded clusters (figure 1C).
Indeed, this restriction of the CSF B-cell repertoire was also
evident at the level of the heavy V gene family usage. In contrast
to the peripheral SM and plasmablast/plasma cell IgG com-
partments, which were diverse and highly comparable, the CSF
IgG repertoire was distinct and restricted (figure 1D).
Next, clusters shared between the CSF and PB were examined
more closely. These shared CSF/PB clusters on average had
990.3 (range 110–1,749) unique sequences. In this analysis, each
unique sequence was represented by a dot and a line joining
neighboring sequences represented a mutational (Hamming)
distance of 1 in their CDR3 region (figure 2A). By definition,
there is at least 1 PB (red) and 1 CSF (blue) sequence in each
cluster. Many shared clusters were dominated by peripheral
B cells and were related to only a small number of CSF B cells.
Also, of interest, several clusters highly dominated by CSF
sequences were apparent and often showed a PB sequence in the
center, representing a more proximal sequence with fewer
Table Patient characteristics of 6 patients with LGI1 encephalitis and 2 controls (bottom 2 rows)
Age Sex
Clinical
presentation
Months from
symptom onset
to DIRS
Response to
glucocorticoid ±
IVIG therapya
CSF WBC
(per 106/
L) OCB
CSF
LGI1
Abs
Serum
LGI1
Abs
Total CSF
IgG
sequencesb
CSF sequences
per shared
clusterc
63 F S, C, A 28 5 to 2 5 0 1:2 1:80 411 8.3
70 M S 8 3 to 2 4 0 1:10 1:1,280 1,749 7.7
72 M S, C, A 22 4 to 2 4 0 1:30 1:2,560 1,604 10.8
57 M S, C, A 51 5 to 2 4 0 ND 1:40 110 3.1
48 F C, A 11 3 to 1 0 0 ND 1:320 1,223 7.8
60 M S, C, A 27 3 to 1 0 0 1:10 1:2,560 845 6.3
35 M Migraine NA NA 0 0 NA NA 43 1.1
58 F Headache NA NA 1 0 NA NA NA NA
Abbreviations: A = amnesia; Abs = antibody levels; C = confusion; DIRS = deep B-cell immune repertoire sequencing; IgG = immunoglobulin G; IVIG = IV
immunoglobulin; LGI1 = leucine-rich, glioma-inactivated 1; NA = not applicable; ND = not detectable; OCB = oligoclonal band (defined as >5 CSF-specific
bands); S = seizure; WBC = white blood cell.
Serum and CSF LGI1 antibody levels are expressed as end-point dilutions on live cell–based assays.
a Modified Rankin score.
b Total number of unique IgG sequences found in the CSF compartment, which are part of clusters connecting the peripheral blood and CSF compartments.
c Mean count of unique CSF sequences in clusters shared across peripheral blood and CSF compartments.
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Figure 1 In patients with leucine-rich, glioma-inactivated 1 antibody encephalitis, deep immune repertoire sequencing of
the immunoglobulin heavy chain variable region (Ig-VH) shows connectivity of class-switched mature peripheral
blood (PB) B cells to clonally expanded CSF B cells/clusters
One representative patient of 6 patients is shown in A–D. (A) Cumulative number of somatic mutations (x-axis) in the IGHV gene nucleic acid sequence
excluding the CDR3 region in nonredundant sequences (count; y-axis) of sorted PB B-cell subsets and CSF B cells are shown for IgM (left panels) and IgG (right
panels). (B) Connectivity of the various PB and CSF B-cell compartments based on clonal relationship is illustrated. While the size of the boxes correlates with
the number of reads in each compartment, the thickness of the connecting line correlates with the number of related sequences between the 2 compart-
ments it connects. For better display, all lines connecting to the CSF IgG compartment are depicted in red, whereas all others are in black. IgG = immuno-
globulin G; IgM = immunoglobulin M; N = naive; PC = plasmablast/plasma cell; SM = switched memory; USM = unswitchedmemory. (C) All clusters of clonally
related Ig-VH that have at least 1 sequence in one of the PB compartments and 1 in the CSF compartments (shared PB andCSF clusters) are depictedwith their
respective size (number of nonredundant sequences) on the y-axis. (D) Frequency of used IGHV genes in the IgG CSF, PB plasmablast/plasma cell, and PB SM
cell subsets.
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Figure 2 Intrathecal somatic hypermutation in patients with leucine-rich, glioma-inactivated 1 (LGI1) antibody encephalitis
(A) Data from1 representative patient of 6 LGI1 patients showing all clusters of clonally related immunoglobulin heavy chain variable region, which are shared
between peripheral blood (PB) and CSF B cells. Each red dot represents ≥1 identical PB sequence, and each blue dot ≥1 identical CSF sequence. Two dots
connected by a line differ from each other by a Hamming distance of 1 in their CDR3 region on the nucleotide sequence level. Clusters of related sequences
are grouped together. (B) Two Ig lineage trees of CSF B cells from1 patient are shown. Each dot represents 1 sequence, and its size correlates with the number
of times this sequence could be found. Two dots connected by a line differ from each other by 1 nucleotide in the CDR3 region unless marked otherwise.
Putative germline nodes are labeled; lineage intermediates not found in the sequencing data were calculated and are labeled in gray.
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mutations from which surrounding CSF sequences may have
descended. More detailed analysis of Ig lineage trees from
clonally relatedCSF IgG-VHdemonstrated intensivemutational
activity, again suggesting intrathecal SHM (figure 2B).
In contrast to all LGI1 antibody encephalitis cases, 2 patients
ultimately diagnosed with noninflammatory neurologic dis-
eases (1 with headache and 1 with chronic migraine), which
were analyzed following the same protocol, did not show
comparable intrathecal B-cell activity. In 1 of the 2 controls,
we were unable to amplify enough CSF IgG RNA for se-
quencing, indicating very few CSF IgG transcripts; in the other,
we were able to detect 43 unique sequences in the CSF, which
were parts of shared CSF/PB clusters compared with 990.3
(mean; range 110–1,749) in LGI1 antibody encephalitis.
Shared clusters in the control were overwhelmingly PB domi-
nated and had on average 1.2 CSF IgG sequences (range 1–3),
whereas shared clusters in patients with LGI1 antibody en-
cephalitis had larger CSF fractions with a mean of 8.1 CSF IgG
sequences (range: mean value per patient 3.4–11.9; minimum/
maximum value per patient across all 6 patients 1/465).
Taken together, DIRS demonstrated high sensitivity in detecting
an intrathecal B-cell response and marked interconnectivity be-
tween the PB and CSF compartments in LGI1 antibody en-
cephalitis, particularly of the more mature B-cell subsets.
However, the antigen specificity of the clonally expanded in-
trathecal B cells remains unclear. Peripheral B-cell expansions
infrequently reached the CSF, but those which did commonly
lead to intrathecal B-cell expansions, consistent with secondary
intrathecal B-cell receptor (BCR) diversification in LGI1 anti-
body encephalitis but not in noninflammatory controls.
Discussion
Here, we examined the potential paradox between the limited
detectable CSF activity in routine clinical assessments (e.g., CSF
cell count and oligoclonal bands), alongside the presence of
pathogenic CNS-active autoantibodies in patients with LGI1
antibody encephalitis. For the first time, using DIRS, we dem-
onstrate highly active intrathecal B-cell activity in LGI1 antibody
patients and show that B-cell repertoires, particularly from post-
germinal center B cells on both sides of the BBB, may actively
mutate and mature in patients with LGI1 antibody encephalitis.
Because, for methodological reasons, our study could not address
the antigen specificity of the intrathecal B-cell response, it
remains to be determined whether these expanded clones rec-
ognize LGI1-specific epitopes, and it is likely that some of these
represent non–LGI1-specific B cells. LGI1-specific CSF B cells
are more likely to exist in the patients in which intrathecal LGI1
antibodies were detectable. However, it cannot be excluded that
LGI1 antibodies have passively diffused to the CSF.
In our studies, we found PB plasmablast/plasma cell IgG-
VHs, which underwent SHM and were related to expanded
clusters of CSF B cells. This pattern closely resembles findings
in MS, suggesting that it may be a generic mechanism across
CNS autoimmune conditions,8,9,13 and accordingly, we did
not observe this phenomenon in noninflammatory controls.
Yet, these observations appear different to the more limited
intrathecal expansions observed in neuromyelitis optica
spectrum disorder and the very low mutational load in CSF
B cells from patients with NMDA receptor (NMDAR) anti-
body encephalitis.14,15 Hence, it may be that several different
immunologic mechanisms operate across these autoantibody-
mediated conditions. Our study did not aim to examine the
antigen-specific population or correlate intrathecal B-cell
responses with clinical outcome. Of interest, it has recently
been observed that intrathecal LGI1 antibody synthesis cor-
relates with a poorer prognosis.16 However, the lack of CSF
LGI1 antibodies in some of our patients with striking in-
trathecal SHM may suggest that DIRS provides a more sen-
sitive measure of B-cell activity.
In general, the majority of autoimmune encephalitis syn-
dromes are considered to be IgG mediated.2,7,16,17 However,
we also found evidence for extensively activated IgM-
expressing peripheral B cells, which share similar or identi-
cal BCR heavy chains to intrathecal IgG-expressing B cells.
The immunopathologic relevance of this IgM response is
unknown, but may indicate an ongoing germinal center
reaction-mediated stimulation of B cells as has been proposed
in patients with NMDAR antibody encephalitis, where IgM
NMDAR-reactive autoantibodies can be detected.18,19
A major question is whether interrupting these responses
could potentially mitigate disease activity, prevent relapses,
and improve long-term cognitive outcomes. Yet, only a subset
of patients with LGI1 antibody encephalitis have been
reported to respond favorably to rituximab, which targets—
mainly peripheral—CD20-expressing B cells and has little
effect on LGI1 antibody production.20 Our findings suggest
that plasmablasts and plasma cells (which do not express
CD20) are active in the CSF, and therefore, novel drugs that
actively target these prolific protein synthesizers in the CNS
compartment might be more effective than selective anti-
CD20 treatments. Conversely, given that affinity maturation
is an ongoing process in LGI1 antibody encephalitis and could
result in increasingly efficient pathogenic antibodies, thera-
peutic depletion of CD20-expressing B-cell populations early
in this disease might prevent development of chronic or
progressive clinical phenotypes. Accordingly, early diagnosis
of intrathecal immune activation in patients with mild clinical
signs would be highly desirable.
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